All In MedTech

FDA Clearance Tracker · P000046-S007

STAARVISC II, SHELLGEL AND COEASE SODIUM HYALURONATE VISCOELASTICS

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 12, 2003 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 12, 2003

Approved

Time to decision

105 days

Received Nov 27, 2002. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P000046-S007
Device name
STAARVISC II, SHELLGEL AND COEASE SODIUM HYALURONATE VISCOELASTICS
Applicant location
Beford, MA
Received
Nov 27, 2002
Decided
Mar 12, 2003
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P000046

Device type

Device class
Class III
Regulation
21 CFR 886.4275
Specialty
Ophthalmology

Every decision under product code LZP

FDA's approval statement

As written in FDA's record.

APPROVAL FOR USE OF AN ALTERNATE RAW MATERIAL SOURCE.

Source documents

Other decisions for Anika Therapeutics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.